CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update
July 27 2017 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will announce financial results for the second
quarter ended June 30, 2017 and provide a mid-year update on August
7, 2017, after the NASDAQ market closing.
Conference Call/Webcast Information
Interested parties may access the live audio webcast of the
teleconference at 5:00 p.m. ET through the Investor and News page
of CytomX's website at http://ir.cytomx.com or by dialing
1-877-809-6037 and using the passcode 61956517. A replay will
be available on the CytomX website or by dialing 1-855-859-2056 and
using the passcode 61956517. The replay will be available
from August 7, 2017, until August 14, 2017.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. Probody therapeutics are
designed to take advantage of unique conditions in the tumor
microenvironment to enhance the tumor-targeting features of an
antibody and reduce drug activity in healthy tissues. The Company
uses its platform to create proprietary cancer immunotherapies
against clinically-validated targets, such as PD-L1, and
first-in-class cancer therapeutics against difficult-to-drug
targets, such as CD166 and CD71. The Company’s lead program,
CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is
being evaluated in a Phase 1/2 study as part of PROCLAIM
(Probody Clinical Assessment In Man),
an international umbrella clinical trial program that provides
clinical trial sites with access to the Company’s novel therapies
under one central protocol. A Phase 1/2 clinical trial for CX-2009,
a first-in-class Probody drug conjugate, targeting the highly
expressed tumor antigen, CD166, is also in progress under the
PROCLAIM umbrella. In addition to its wholly owned programs, CytomX
is collaborating with strategic partners,
including AbbVie, Bristol-Myers Squibb
Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. BMS expects to advance
its first collaboration product candidate, a Probody therapeutic
targeting CTLA-4, into clinical studies in early 2018. CytomX, in
collaboration with AbbVie, expects to advance the
CD71-targeting Probody Drug Conjugate, CX-2029, into clinical
studies in 2018. For more information,
visit www.cytomx.com or follow us on Twitter.
Media Contact:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024